India Women’s Health Therapeutics Market: A Growth Story Shaped by Awareness and Access
Women’s health has long been an underserved segment of healthcare in India, but this is changing rapidly as awareness grows, healthcare infrastructure expands, and pharmaceutical companies increasingly focus their innovation pipelines on conditions that disproportionately affect women. The India Women’s Health Therapeutics Market is at the center of this transformation, encompassing drugs and therapies for contraception, dysmenorrhea, hormone replacement, bone health, acne, and related conditions. As more women seek timely diagnosis and treatment for reproductive and hormonal health issues, the therapeutics ecosystem supporting them is expanding in scale and sophistication.
Market Size and Growth Trajectory
The numbers tell a compelling story of expansion. The India women’s health therapeutics market was valued at USD 1.98 billion in 2021 and is projected to grow from USD 2.22 billion in 2022 to USD 5.98 billion by 2029, registering a robust CAGR of 15.2% during the forecast period, according to Fortune Business Insight. This growth rate reflects not just population-driven demand but a structural shift in how women’s health is perceived and addressed across urban and increasingly rural India.
The pandemic years, however, told a more complicated story. The market witnessed a decline of 4.8% in 2020 compared to 2019, according to Fortune Business Insight, as COVID-19 disrupted healthcare access across the country. Non-essential diagnoses and procedures were postponed to conserve resources for pandemic response, and millions of women temporarily lost access to routine reproductive healthcare services, including contraception and abortion care.
The Burden of Women’s Health Disorders
A central driver of this market is the sheer prevalence of health conditions affecting Indian women. Conditions such as dysmenorrhea, Polycystic Ovary Syndrome (PCOS), and osteoporosis are becoming increasingly common, partly fueled by sedentary urban lifestyles and reduced physical activity among younger demographics.
The scale of this burden is striking. Approximately 23% of Indian women reported missed periods, and an estimated 18% increase in PCOS cases was observed, largely attributed to inactive lifestyles among young adults, according to Fortune Business Insight. Separately, the prevalence of PCOS in India was estimated at around 22.5% in 2021, according to Fortune Business Insight, underscoring how widespread this hormonal disorder has become among women of reproductive age.
Bone health is another area of growing concern. An estimated 46 million Indian women were suffering from osteoporosis in 2021, according to Fortune Business Insight, highlighting the need for therapeutic interventions targeting skeletal health, particularly among postmenopausal women.
Pandemic Disruptions and Recovery
The COVID-19 pandemic created a unique set of challenges for women’s health access in India. Ironically, even as health complications rose during lockdowns, the ability to seek treatment diminished sharply. Nearly 30% increase in PCOS cases was observed among women aged 25-30 years due to inactivity during the pandemic, according to Fortune Business Insight, even as healthcare systems buckled under COVID-19 caseloads.
The access gap was severe during the initial pandemic months. Between January and June 2020, an estimated 1.3 million Indian women lost access to abortion and contraceptive services, according to Fortune Business Insight. Injectable contraceptive administration also fell sharply, with an estimated 36% decrease recorded during the 2019-2020 period, according to Fortune Business Insight. As normalcy gradually returned, the resumption of treatment procedures for acne, hormonal therapy, and other conditions has helped the market regain its growth momentum.
Digital Transformation in Drug Access
One of the more notable trends reshaping this market is the shift from traditional retail pharmacies to online drug purchasing channels. The growth of e-commerce platforms and the entry of major players into online pharmacy networks, including Amazon’s move into online pharmacy distribution in August 2020, has made contraceptives and other women’s health drugs far more accessible, particularly in remote and underserved regions.
This digital shift extends beyond urban centers. An estimated 64.7% of the population in rural areas of Maharashtra were using modern contraceptive methods, according to Fortune Business Insight, pointing to meaningful progress in contraceptive adoption even outside major metropolitan areas.
Market Segmentation and Competitive Dynamics
By application, the market spans contraceptive drugs, dysmenorrhea therapeutics, antibiotics, antifungals, hormone replacement, acne treatment, bone health, and other categories. The contraceptive drugs segment held the dominant share in 2021, driven largely by unmet contraceptive needs among adolescent women. Approximately 2.4 million adolescent women in India wanted to avoid pregnancy but lacked access to modern contraception, according to Fortune Business Insight, a gap that continues to fuel demand in this segment.
Meanwhile, the hormone replacement therapy segment is expected to grow at a particularly strong pace during the forecast period, driven by rising menopausal symptom management needs among India’s aging female population.
The competitive landscape features a mix of established domestic and multinational players. Companies including Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Inc., Abbott, Lupin, Bayer AG, Glenmark Pharmaceuticals Limited, Granules India Limited, and Emami Limited are actively shaping the market through new product launches, partnerships, and acquisitions. Recent developments include Cipla’s launch of its Evexpert intimate wash in March 2022, Dr. Reddy’s distribution agreement with Novartis India in February 2022, and Bayer AG’s acquisition of KaNDy Therapeutics Ltd. in September 2020 to strengthen its women’s healthcare pipeline.
Restraints: Alternatives and Generics
Despite the positive growth outlook, the market faces headwinds. The availability of alternative treatment options, such as female sterilization, copper T devices, and laser therapy, continues to limit adoption of pharmaceutical therapeutics for some conditions. Additionally, a strong consumer preference for lower-cost generic medicines over branded drugs continues to constrain the growth potential of premium therapeutic products, even as overall category awareness increases.
Looking Ahead
The India women’s health therapeutics market sits at an important inflection point. Rising disease prevalence, growing awareness, expanding digital access to medicines, and sustained investment from both domestic and global pharmaceutical players are converging to drive meaningful growth through 2029. While affordability pressures and alternative treatment options will continue to shape adoption patterns, the overall trajectory points toward a more accessible, better-resourced women’s healthcare ecosystem in India in the years ahead.
What’s Driving Japan’s Market? Discover the Latest “Japan Women’s Health Therapeutics Market” Insights